Clinical Trials Logo

Clinical Trial Summary

To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10^9/L to 100 x 10^9/L. It is anticipated that individualized dose optimization from the starting ruxolitinib level of 5 mg bid will be associated with reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01348490
Study type Interventional
Source Incyte Corporation
Contact
Status Completed
Phase Phase 2
Start date June 15, 2011
Completion date December 19, 2018

See also
  Status Clinical Trial Phase
Terminated NCT03123588 - Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) Phase 2
Completed NCT02252159 - Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
Completed NCT01633372 - An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis Phase 2
Completed NCT03144687 - A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Phase 2
Terminated NCT02718300 - A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Phase 2
Completed NCT02953704 - Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Completed NCT00952289 - COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Phase 3
Active, not recruiting NCT03011372 - A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) Phase 2